SA post: Lexington Provides Q3 Corporate ReviewGlobal Newswire.Lexington Provides Q3 Corporate Review can be viewed at:
https://seekingalpha.com/pr/17309940-lexington-provides-q3-corporate-review Tue October 23, 2018 6:37 PM|GlobeNewswire|About: LXGTF
VANCOUVER, British Columbia, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Lexington Biosciences, Inc. (CSE: LNB) (OTCQB: LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, is pleased to review activities undertaken during Q3 of 2018.
Over the summer, the Company completed its first phase of clinical testing at Diablo Clinical Research. The results of the study validated safety protocols, provided the Company with critical information for product iteration, algorithm development, and clinical testing protocol refinement in preparation for the upcoming multi-center clinical study series.
During this same period, the Company commenced a brokered private placement offering in Canada that ultimately was unsuccessful due to prevailing market conditions. Currently, the Company has a non-brokered private placement open which is anticipated to close during Q4. As a result of investment market uncertainty, the Company has been operating in capital preservation mode, and as a result, the previously published timelines and strategic planning have been extended.
For complete article - go to above link.
I am long on this but Cheers to all investors!